Thymosin Alpha-1 vs TA-1 — Same Compound?

Thymosin Alpha-1 vs TA-1 — Same Compound? Thymosin alpha-1 and TA-1 are the same 28-amino-acid peptide — the abbreviation TA-1 refers to the full compound thymosin alpha-1, not a separate molecule. Most researchers encounter the abbreviation 'TA-1' in peptide literature and assume it's a derivative or variant of thymosin alpha-1. It's not. The confusion stems from inconsistent naming conventions across published studies. Some papers use the full name, others default to the abbreviation, and the lack of standardisation creates the impression that two distinct compounds exist. What actually exists is one peptide with two names. Our team has supplied research-grade peptides to laboratories across multiple therapeutic areas for years. The single most common question we field about thymosin alpha-1 is whether TA-1 represents a modified form with altered immunomodulatory properties. The answer is definitive: no modification exists. TA-1 is thymosin alpha-1. Same sequence, same mechanism, same molecular weight. What's the difference between thymosin alpha-1 and TA-1? Thymosin alpha-1 and TA-1 are the same 28-amino-acid peptide. TA-1 is simply the abbreviated form of thymosin alpha-1, used interchangeably in research and clinical contexts. Both refer to the identical polypeptide derived from prothymosin alpha, with a molecular weight of 3,108 Da and the same immunomodulatory mechanism of action. No structural, functional, or clinical difference exists between the two names. The terminology split exists purely for convenience. Early immunology research in the 1970s established 'thymosin alpha-1' as the formal nomenclature after the peptide was first isolated from calf thymus tissue at the University of Texas Medical Branch. As research volume increased, investigators defaulted to 'TA-1' to streamline citations and abstract text. Both names appear in peer-reviewed literature without distinction. The Journal of Immunology, Clinical Immunology, and Immunopharmacology journals use them interchangeably. This article covers the origin of the nomenclature, why the abbreviation persists, and what researchers should verify when sourcing either form. Thymosin alpha-1 (TA-1) is a 28-amino-acid polypeptide cleaved from the N-terminal region of prothymosin alpha, a 109-amino-acid precursor protein expressed in the thymus gland. The sequence is identical regardless of which name appears on the vial label: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. The acetylated serine at position 1 and the free carboxyl group at position 28 define the molecular boundaries. Any variation in this sequence produces a functionally distinct peptide. The molecular weight is 3,108 Da. The isoelectric point is approximately 4.2, making TA-1 acidic under physiological pH. These parameters remain constant whether the compound is labeled thymosin alpha-1, TA-1, or thymalfasin (the international nonproprietary name assigned by the World Health Organization). Suppliers who list 'TA-1' and 'thymosin alpha-1' as separate catalog entries are describing the same molecule. Verify the amino acid sequence and molecular weight rather than relying on the product name alone. Our experience working with laboratories sourcing this peptide shows that sequence verification matters more than nomenclature. We've encountered instances where suppliers listed 'thymosin alpha' without the '-1' designation. That refers to thymosin fraction 5, a crude extract containing multiple peptides, not the purified 28-amino-acid compound. Real peptides are synthesized with exact amino-acid sequencing to ensure that every batch matches the published TA-1 structure precisely. The abbreviation TA-1 emerged in the early 1980s as immunology research expanded beyond initial thymic peptide characterisation studies. Allan Goldstein's group at George Washington University published foundational work on thymosin alpha-1's role in T-cell maturation, and subsequent investigators adopted the shortened form to streamline citations in methods sections and figure legends. The shift wasn't formalised by a nomenclature committee. It happened organically as publication volume increased. PubMed searches reveal the pattern clearly. A query for 'thymosin alpha-1' returns approximately 1,200 citations; 'TA-1' returns roughly 800. The overlap is substantial. Many papers use both terms within the same manuscript, defining TA-1 parenthetically after the first use of thymosin alpha-1. This dual usage persists because no regulatory or editorial standard mandates one form over the other. The International Union of Pure and Applied Chemistry (IUPAC) recognises thymosin alpha-1 as the formal name, but IUPAC guidelines don't govern how researchers label reagents in laboratory protocols. For practical purposes, both names function identically in supplier catalogs, Certificate of Analysis documents, and Material Safety Data Sheets. What matters is the accompanying analytical data: HPLC purity (target ≥95%), mass spectrometry confirmation of the 3,108 Da molecular weight, and endotoxin levels (typically <1.0 EU/mg for cell culture applications). The name on the label is secondary to the validation that the peptide inside the vial matches the published TA-1 sequence. Thymosin alpha-1 appears under additional names in clinical trial literature and regulatory filings. Thymalfasin is the WHO-designated international nonproprietary name (INN), used in Phase III trials conducted in China, Italy, and other regions where the peptide has been evaluated for hepatitis B, hepatitis C, and sepsis. Zadaxin is the branded formulation marketed by SciClone Pharmaceuticals (now Viatris) in select international markets. It contains the same 28-amino-acid TA-1 sequence at 1.6 mg per subcutaneous injection. These naming variants don't indicate structural modification. Thymalfasin and Zadaxin refer to the pharmaceutical-grade formulation of thymosin alpha-1, prepared under Good Manufacturing Practice (GMP) standards for human use. Research-grade TA-1 supplied for in vitro and preclinical studies follows similar synthesis pathways. Solid-phase peptide synthesis (SPPS) using Fmoc chemistry. But without the additional validation required for injectable drug products. The peptide sequence remains identical across all applications. One area where nomenclature confusion persists involves thymosin beta-4 (Tβ4), a separate 43-amino-acid peptide also derived from thymic tissue. Tβ4 and TA-1 are structurally and functionally distinct. Tβ4 binds actin and regulates cytoskeletal dynamics, while TA-1 modulates T-cell differentiation through interactions with Toll-like receptors (TLRs) and the nuclear factor kappa B (NF-κB) pathway. Suppliers occasionally group both peptides under 'thymosin peptides' in catalog sections, which can obscure the fact that they're unrelated compounds. Verify the sequence and molecular weight when ordering to avoid receiving the wrong peptide. Research-grade in vitro studies Standard nomenclature in methods sections Abbreviated form in figures and legends Not applicable. Clinical formulation only Both names refer to the same peptide. Verify sequence and purity via COA Preclinical animal models Used in dosing protocols and pharmacokinetic analysis Common in immunology journals Not applicable Nomenclature choice reflects publication style, not compound identity Clinical trial documentation Formal INN name in regulatory filings Rare in clinical literature WHO-designated name for pharmaceutical product Thymalfasin = thymosin alpha-1 = TA-1 at the molecular level Commercial drug product (international markets) Generic descriptor Not used in branding Branded formulation (1.6 mg subcutaneous) Zadaxin contains TA-1. Same sequence, GMP manufacturing Supplier catalogs Full chemical name Abbreviated catalog listing Not sold as research-grade reagent Both listings describe identical 28-amino-acid peptide Regulatory filings (FDA, EMA) Required formal name Acceptable parenthetical abbreviation Designated INN for drug approval All three terms may appear in the same regulatory document Thymosin alpha-1 and TA-1 are the same 28-amino-acid peptide. TA-1 is the abbreviated form, used interchangeably in research and clinical contexts without indicating a structural or functional difference. The sequence is identical regardless of nomenclature: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, with a molecular weight of 3,108 Da. Thymalfasin and Zadaxin are additional names for the same compound. Thymalfasin is the WHO international nonproprietary name, and Zadaxin is the branded pharmaceutical formulation. Verify the amino acid sequence and molecular weight on the Certificate of Analysis when sourcing peptides. Nomenclature alone doesn't confirm compound identity. Thymosin beta-4 (Tβ4) is a separate, structurally distinct peptide. It's not a variant of TA-1 and serves different biological functions related to cytoskeletal regulation rather than immune modulation. Request the Certificate of Analysis (COA) for each listing and compare the amino acid sequence and molecular weight. If both COAs show the same 28-amino-acid sequence and 3,108 Da molecular weight, the products are identical. The supplier is using redundant catalog entries. If the sequences differ, one product may be a thymosin fraction or a modified analog rather than the defined TA-1 peptide. Sequence verification is the only reliable way to confirm that both listings describe the same compound, and any reputable supplier will provide HPLC and mass spectrometry data upon request. Assume the abbreviation refers to thymosin alpha-1 unless the paper explicitly states otherwise. The convention in immunology and peptide research is that TA-1 defaults to thymosin alpha-1. No other peptide shares this abbreviation in published literature. If the study involves thymic extracts or crude fractions, the authors will specify 'thymosin fraction 5' or 'crude thymosin' rather than TA-1. Cross-reference the methods section for the peptide source and molecular weight to confirm the identity if any ambiguity exists. Minor variation (±2 Da) can result from mass spectrometry ionisation artifacts or the presence of residual trifluoroacetic acid (TFA) from HPLC purification, which can add mass without altering the peptide sequence. A difference exceeding 5 Da suggests either an incomplete synthesis (missing amino acids) or the presence of a contaminant. Request a replacement or ask the supplier to provide a detailed mass spectrum showing the expected [M+H]+ ion at 3,109 Da. Authentic TA-1 should produce a clean single peak within the expected range. Here's the honest answer: the persistence of dual nomenclature for thymosin alpha-1 and TA-1 isn't a scientific distinction. It's a historical artifact that suppliers and researchers perpetuate because neither group has a compelling reason to standardise. The peptide community tolerates redundant naming because the stakes are low: as long as the sequence matches, the name doesn't affect function. What does matter is recognising that nomenclature inconsistency creates vulnerability to sourcing errors. A laboratory ordering 'TA-1' from a supplier that doesn't verify the sequence could receive thymosin beta-4, thymosin fraction 5, or a truncated analog. All of which appear under 'thymosin' umbrella terms in some catalogs. The solution isn't to eliminate the abbreviation. It's to treat the COA as the definitive source of truth and ignore the product name entirely. Thymosin alpha-1 and TA-1 are the same peptide. If a supplier, publication, or protocol suggests otherwise, verify the sequence. That's the only data point that matters. Understanding this saves time, prevents sourcing mistakes, and ensures that the compound used in research matches the published literature exactly. Which is what small-batch synthesis with exact amino-acid sequencing is designed to guarantee across our full peptide collection. Yes — TA-1 is the abbreviated form of thymosin alpha-1. Both names refer to the same 28-amino-acid peptide with a molecular weight of 3,108 Da. The abbreviation TA-1 emerged in research literature for citation convenience, but the peptide sequence, structure, and mechanism of action are identical. Suppliers and researchers use the terms interchangeably. Thymosin alpha-1 (TA-1) and thymosin beta-4 (Tβ4) are structurally and functionally distinct peptides. TA-1 is a 28-amino-acid immunomodulatory peptide that regulates T-cell differentiation, while Tβ4 is a 43-amino-acid peptide that binds actin and influences cytoskeletal dynamics. Despite both originating from thymic tissue, they serve unrelated biological roles and cannot be substituted for one another in research protocols. Yes — thymalfasin is the international nonproprietary name (INN) assigned by the World Health Organization for thymosin alpha-1. It refers to the same 28-amino-acid peptide used in clinical trials and pharmaceutical formulations. Zadaxin, the branded drug product, also contains thymalfasin (TA-1) at 1.6 mg per subcutaneous injection. All three names describe the identical molecular structure. Request the Certificate of Analysis (COA) and confirm that the amino acid sequence matches the published TA-1 structure: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. The molecular weight should be 3,108 Da (±2 Da), HPLC purity should exceed 95%, and mass spectrometry should show a clean peak at 3,109 Da. Nomenclature alone doesn’t confirm identity — sequence validation is the definitive test. The choice reflects publication style and citation convenience rather than a scientific distinction. Early immunology research established thymosin alpha-1 as the formal name, but as the field expanded, investigators adopted TA-1 to streamline methods sections and figure legends. Both terms appear in peer-reviewed journals without indicating a difference in compound identity — many papers define TA-1 parenthetically after the first use of thymosin alpha-1. Yes — as long as the amino acid sequence and purity are verified, both names describe the same peptide and can be used interchangeably. The critical factor is confirming that the supplier’s product matches the published TA-1 sequence via Certificate of Analysis documentation. Nomenclature consistency within a single manuscript is recommended for clarity, but switching between terms across studies doesn’t affect reproducibility if the peptide structure remains identical. Thymosin fraction 5 is a crude extract from thymic tissue containing multiple peptides, including thymosin alpha-1, thymosin beta-4, and other thymic factors. It is not a purified compound — TA-1 refers specifically to the isolated 28-amino-acid thymosin alpha-1 peptide. Suppliers who list ‘thymosin alpha’ without the ‘-1’ designation may be offering fraction 5 rather than purified TA-1. Always verify the se